Treating Arthritis in Canines

Introducing monoclonal antibodies – a promising new approach to treating dogs suffering from arthritis, by reducing pain and inflammation in canine joints.

Introducing monoclonal antibodies – a promising new approach to treating dogs suffering from arthritis, by reducing pain and inflammation in canine joints.

Arthritis is a common condition that affects many dogs, particularly as they age. Arthritis can cause pain, stiffness, and inflammation in the joints. Naturally, this can make it difficult for dogs to move and perform normal activities. While there are a variety of treatments available for arthritis in dogs, one promising new approach is the use of monoclonal antibodies.

What are monoclonal antibodies?

Monoclonal antibodies are a type of protein designed to target specific cells or molecules in the body. They are created in a laboratory by cloning a single type of immune cell. They are then customized to target specific proteins or molecules involved in disease processes.

In the case of arthritis, monoclonal antibodies can be designed to target specific molecules contributing to inflammation and joint damage. In doing so, they can help reduce inflammation and slow the progression of arthritis.

Monoclonal antibodies in action against arthritis

One example of a monoclonal antibody being used to treat arthritis in dogs is Canine Anti-NGF. This targets a protein called nerve growth factor (NGF), which is involved in pain sensation and inflammation in the joints. By blocking NGF, Canine Anti-NGF can reduce pain and inflammation in dogs with arthritis.

Studies have shown that Canine Anti-NGF can be effective in reducing pain and improving mobility in dogs with arthritis. In one study, dogs treated with Canine Anti-NGF showed significant improvements in pain scores and mobility compared to dogs treated with a placebo.

In addition to Canine Anti-NGF, there are other monoclonal antibodies being developed and tested for the treatment of arthritis in dogs. These include antibodies that target other molecules involved in inflammation and joint damage, such as:

  • interleukin-1 (IL-1), and
  • tumor necrosis factor alpha (TNF-alpha).

Potential side effects

While monoclonal antibodies show promise as a treatment for arthritis in dogs, they are not without potential side effects. Like any medication, monoclonal antibodies can cause adverse reactions, such as allergic reactions, and they may not be suitable for all dogs.

It is important to discuss all treatment options with your veterinarian to determine the best approach for your dog’s individual needs.


Dr. Omer Rashid earned his veterinary degree in 2002 from University of Agriculture Faisalabad, and quickly followed that with a Master’s degree in Parasitology. He worked for several years in veterinary practice with small animals, as well as horses and livestock. He studied advanced pharmacology at Charles Darwin University in Australia, and discovered his love for writing while working as a science writer for a research company with clients such as Harvard, Stanford and Cambridge universities. Along the way, Dr. Rashid developed an interest in integrative veterinary health, and he joined Redstone Media Group as Associate Editor of IVC Journal and veterinary content developer in 2022.